| Literature DB >> 34310025 |
Mónica Sancho1, Diego Leiva1, Estefanía Lucendo1, Mar Orzáez1.
Abstract
Myeloid cell leukemia-1 (MCL1), an antiapoptotic member of the BCL2 family characterized by a short half-life, functions as a rapid sensor that regulates cell death and other relevant processes that include cell cycle progression and mitochondrial homeostasis. In cancer, MCL1 overexpression contributes to cell survival and resistance to diverse chemotherapeutic agents; for this reason, several MCL1 inhibitors are currently under preclinical and clinical development for cancer treatment. However, the nonapoptotic functions of MCL1 may influence their therapeutic potential. Overall, the complexity of MCL1 regulation and function represent challenges to the clinical application of MCL1 inhibitors. We now summarize the current knowledge regarding MCL1 structure, regulation, and function that could impact the clinical success of MCL1 inhibitors.Entities:
Keywords: BCL2 family; MCL1; MCL1 inhibitor; apoptosis; cell cycle
Mesh:
Substances:
Year: 2021 PMID: 34310025 DOI: 10.1111/febs.16136
Source DB: PubMed Journal: FEBS J ISSN: 1742-464X Impact factor: 5.622